Trial Profile
A Multicenter, International, Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Crizotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational
- Sponsors Roche; Roche Farma
- 18 Apr 2023 Status changed from active, no longer recruiting to recruiting.
- 16 Oct 2022 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 20 Apr 2022 This trial has been completed in Spain, according to European Clinical Trials Database record.